Authors
Latest:
Sacituzumab Govitecan Combo Yields Early Activity in Metastatic NSCLCData from the phase 2 EVOKE-02 trial support further assessment of sacituzumab govitecan plus pembrolizumab as a frontline treatment for metastatic non–small cell lung cancer.
Latest:
Jason Williams, MD, on Intratumoral Immunotherapy Advances at SITC 2019Jason Williams, MD, discusses the development of intratumoral immunotherapy, as well as trial results from his poster presentation at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Latest:
Joshua Brody, MD, on Cross-Section of Science and Medicine at SITC 2019Joshua Brody, MD, discusses the gratification of the crossover between medicine and science at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Latest:
Experts Identify Steps to Improve Representation of African Americans in Multiple Myeloma Studies“The importance of diverse representation cannot be underscored enough and is critical to ensure that safe and effective products are available to the [United States] patient population,” wrote the study authors, who were led by Nicole Gormley, MD.
Latest:
Robert Ferris, MD, on Immunotherapy Transforming Cancer TreatmentRobert Ferris, MD, from UPMC Hillman Cancer Center, discusses the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019), and how immunotherapy will continue to transform cancer treatment.
Latest:
What Are the Most Common Esophageal MetastasesA rare occurrence, cancer in the esophagus requires an individualized treatment plan.
Latest:
Putting Amivantamab Plus Lazertinib Into PracticePanelists discuss key takeaways from the analysis of long-term results, noting that these findings may influence their recommendations for first-line regimens in EGFR-mutant metastatic non–-small cell lung cancer. They highlight how they engage patients in discussions about treatment options, considering efficacy and safety, while addressing remaining unmet needs in this therapeutic area.
Latest:
The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer PatientGeriatric assessments have now been recommended as part of the standard evaluation of an older adult considering cancer therapy.
Latest:
Polatuzumab Vedotin Regimen Yields ‘Meaningful’ Benefit in DLBCL, Expert SaysPolatuzumab vedotin-piiq plus R-CHP can reduce the need for any subsequent lines of therapy for patients with diffuse large B-cell lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
Latest:
The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer PatientGeriatric assessments have now been recommended as part of the standard evaluation of an older adult considering cancer therapy.
Latest:
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLLThe treatment landscape for chronic lymphocytic leukemia has dramatically changed in the past decade.
Latest:
CLL14 Trial: Fixed-Duration Chemotherapy-Free Regimen for Frail Patients with Treatment-Naïve CLLThe treatment landscape for chronic lymphocytic leukemia has dramatically changed in the past decade.
Latest:
Domenico Mallardo, MD, on Anti-CTLA4 Agents in MelanomaDomenico Mallardo, MD, Istituto Nazionale Tumori "Fondazione Pascale" in Naples, discusses results from his trial – designed to evaluate anti-CTLA4 agents in patients with melanoma who relapsed on treatment with ipilimumab (Yervoy), which was presented at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Latest:
Luca Biavati, MD, on Bone Marrow T-Cells for Adoptive Cell TherapyLuca Biavati, MD, from Johns Hopkins Medicine, discussed bone marrow T-cells and bone marrow infiltrating lymphocytes as a source for adoptive cell therapy at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Latest:
What Are the Most Common Esophageal MetastasesA rare occurrence, cancer in the esophagus requires an individualized treatment plan.
Latest:
Marjorie Zauderer, MD, on New Immunotherapy ApproachesMarjorie Zauderer, MD, from Memorial Sloan Kettering Cancer Center, discussed new immunotherapy approaches at the 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019).
Latest:
Kathryn Arbour, MD, on the Development of KRAS G12C Inhibitors in Lung CancerThe MSK expert discusses exciting advancements in the field of immunotherapy for treating lung cancer at the Annual New York Lung Cancers Symposium®.
Latest:
David Braun, MD, PhD, on the Unique Experiences at IKCSThe next gen innovator discusses the integration of fields at the International Kidney Cancer Symposium in Miami.
Latest:
ONCOLOGY Remembers Dr Franco MuggiaONCOLOGY remembers Dr Franco Muggia's contribution to cancer care.
Latest:
Stephen Liu, MD, on Key Takeaways From the ARROW Trial of Pralsetinib for RET+ NSCLCAt ASCO 2021, CancerNetwork® spoke with Stephen Liu, MD, about his research on the ARROW trial and how these results might impact the treatment of patients with RET fusion–positive non–small cell lung cancer who are potential candidates for treatment with pralsetinib.
Latest:
Poulikos Poulikakos, PhD, on Combining Targeted Therapy and Immunotherapy in MelanomaPoulikos Poulikakos, PhD, discussed combining targeted therapy and immunotherapy for the treatment of patients with melanoma at the 16th International Congress of the Society for Melanoma Research.
Latest:
Kunal Rai, PhD, Discusses Genomic Alterations in Melanoma TherapyThe MD Anderson Cancer Center expert discussed how researchers are using genetic alterations to drive specific therapies at the 16th International Congress of the Society for Melanoma Research.
Latest:
Richard White, MD, PhD, Discusses His Research into Why Melanoma MetastasizesThe Memorial Sloan Kettering Cancer Center expert discussed a study he designed to discover why and how melanoma metastasizes, at the 16th International Congress of the Society for Melanoma Research.
Latest:
Kevin M. Sullivan, MD, Discusses Treatment Expansion in Lung CancerKevin M. Sullivan, MD, from the Northwell Health Cancer Institute, discussed how the options for treatment of patients with lung cancer have expanded greatly at the Annual New York Lung Cancers Symposium®.
Latest:
NSCLC Treatment: MET Exon 14 Skipping Mutations and RET RearrangementsBalazs Halmos, MD, and the Oncology Brothers discuss therapeutic practices for patients with NSCLC, highlighting how MET exon 14 skipping mutations and RET rearrangements inform treatment decisions.
Latest:
Brendon M. Stiles, MD, Discusses Low-Dose Radiation Therapy Along with ImmunotherapyThe thoracic surgeon from NewYork-Presbyterian Hospital discusses a trial at the institution in which they give low-dose radiation therapy along with immunotherapy at the Annual New York Lung Cancers Symposium®.
Latest:
Addressing Disparities Through the Enhancing Oncology Model and the Opportunity With Medically Integrated DispensingCancerNetwork spoke with AmerisourceBergen's Lisa Harrison, RPh, about how the new Enhancing Oncology Model and medically integrated dispensing factor into combating health disparities.
Latest:
ALLO-715, Off-the-Shelf CAR T-Cell Therapy, Produces Early Promise in Multiple MyelomaAn off-the-shelf CAR T-cell therapy that targets B-cell maturation antigen, ALLO-715, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.
Latest:
Pembrolizumab Plus Chemoradiation Therapy Yields Promising Results for Patients with Unresectable, Locally Advanced NSCLCFollow up data from KEYNOTE-799 demonstrated a high overall response rate with no new safety signals for patients with unresectable, locally advanced, stage III non-small cell lung cancer.
Latest:
Matthew S. Davids, MD, MMSc, Discusses Extended Use of Venetoclax in CLLMatthew S. Davids, MD, MMSc, spoke about the benefit of venetoclax combinations in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
